Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Total Asset Turnover
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Biogen Inc., total asset turnover, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands


The financial data reflects several notable trends in the company's operational and financial metrics over the analyzed period.

Revenues
Revenues displayed a general upward trend from 2005 through 2019, increasing from approximately $2.42 billion in 2005 to a peak near $14.38 billion in 2019. This represents a substantial growth over the 14-year span. However, after reaching this peak, revenues declined significantly in the subsequent two years, falling to approximately $13.44 billion in 2020 and further to about $10.98 billion in 2021. This downward movement after 2019 suggests challenges in maintaining top-line growth in recent years.
Total Assets
Total assets showed a steady expansion from 2005 until 2019, growing from approximately $8.37 billion to about $27.23 billion, nearly tripling over this period. The growth trend suggests ongoing investments and asset accumulation consistent with expanding operations. However, from 2019 onwards, total assets declined to about $24.62 billion in 2020 and further to roughly $23.88 billion in 2021, indicating possible divestitures, asset impairments, or restructuring efforts during this period.
Total Asset Turnover
The total asset turnover ratio, an efficiency measure indicating how effectively assets generate revenue, improved markedly from 0.29 in 2005 to a peak of 0.68 in 2014. This increase indicates enhanced efficiency in using assets to produce revenue through this period. Following 2014, the ratio decreased and stabilized around the mid-0.5 range, ending at 0.46 in 2021. This decline, coupled with the recent reductions in revenues and total assets, may reflect diminished operational efficiency or changes in asset structure impacting revenue generation capacity.

In summary, the data illustrates a period of strong growth in revenues and assets up to 2019, accompanied by improved asset utilization efficiency until around 2014. Post-2019, there are signs of contraction in both revenue and asset base, along with a decrease in asset turnover efficiency, which could indicate strategic shifts, market challenges, or operational issues affecting performance.


Comparison to Competitors

Biogen Inc., total asset turnover, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Biogen Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)